Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects.

In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors.

Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables.

All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%.

Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.

The authors declare no competing or financial interests. No funding was received for this study.

Principles of Declaration of Helsinki were followed in this retrospective analysis.

R.B.S. conceived the idea and revised the manuscript. S.K.J. collected the data and wrote the manuscript. K.V. analyzed the data and also contributed to writing the manuscript.

Received: 02 October 2024

Accepted: 24 March 2025

Article published online:
23 April 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India